BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200728
DTEND;VALUE=DATE:20200729
DTSTAMP:20260729T201411
CREATED:20200711T141810Z
LAST-MODIFIED:20200723T135535Z
UID:21522-1595894400-1595980799@ces.b2sg.org
SUMMARY:Epigenetic Therapeutic Targets
DESCRIPTION:The Epigenetic Therapeutic Targets meeting brings together academic and industry leaders in the field of epigenetics. These include:\n\n  \nSTORM therapeutics / AstraZeneca / GSK / Oryzon Genomics / Incyte / EpiZyme / 4SC / Bluebird Bio / Bristol Myers Squibb / Prelude Therapeutics / Corvidia Therapeutics / Foghorn Therapeutics / Epigeneron / Abcam / Salarius Pharmaceuticals / Twentyeight-Seven Therapeutics / aTyr Pharma / Epitoire / Epic Therapeutics / Constellation Pharmaceuticals / Vertex / Volition / Novartis / Imago Biosciences / Omega Therapeutics / Genentech / Resverlogix Corp / Accent Therapeutics / Johns Hopkins Medicine / Zenith Epigenetics / Imperial College London / Ohio State University / University of Rome La Sapienza / Viracta Therapeutics / Cancer Epigenetics Society / Dovetail Genomics / University of California San Diego \n\nMeeting program:\n\n7:30 am Online speed networking\n\nSynopsis\nGrab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking! \n\n\n\n8:00 am Opening Keynote Address: Chromatin-modifying and RNA-modifying Enzyme Inhibitors as Precision Cancer Therapeutics\n\nRobert Copeland\, President\, Chief Scientific Officer and Co-Founder \, Accent Therapeutics\n\n\n\nSynopsis\n\nThe history of epigenetics – from first wave to present day \nBenefits of RNA modifying enzymes as a target \nPrecise combination therapeutics in cancer (including epigenetics) for patients in the future \n\n\n\n\n8:30 am Targeting cancer with first-in-class inhibitors of the RNA m6A methyltransferase METTL3\n\nMark Albertella\, Vice President\, Translational Oncology\, Storm Therapeutics\n\n\n\nSynopsis\n\nIntroduction to RNA modifications\, the role of METTL3 and the m6A modification on selected mRNA species\nOverview of our drug discovery efforts to identify potent and selective inhibitors of METTL3\nCharacterisation of potent\, selective\, bioavailable inhibitors of METTL3 in biochemical\, biophysical and cellular assays\nExploration of utility of METTL3 inhibitors in hematological and solid tumour cell lines\nDemonstration of in vivo activity of METTL3 inhibitors in hematological and solid tumour models\n\n\n\n\n9:00 am From Somatic Mutations to Chromatin Topology – Emerging Tools For Epigenetic Biomarker Discovery\n\nTodd Dickinson\, CEO\, Dovetail Genomics\n\n\n\nSynopsis\n\nIntroduction to Omni-C\, a single assay for SNP detection\, SV mapping and\nchromatin 3-D landscape characterization\nInsights into drug response by capturing the 3-D gene regulatory landscape\nChromatin topology improves cancer genome characterization\nEnhancing bio-marker discoveries with genome topology\n\n\n\n\n9:15 am Overcoming Therapy Resistance to Cancer Immune Therapy – The role of epigenetic modulators\n\nSvetlana Hamm\, Head of Research and Translational Medicine\, 4SC\n\n\n\nSynopsis\n\nCancer immunophenotypes and immune escape mechanisms – how to address resistance to immune checkpoint therapy\nImmunomodulatory features of epigenetic drugs – rationale selection of combinations\, dose\, and schedule\nCase studies: i) Broad-spectrum HDAC inhibitor resminostat in combination with opsonizing antibodies in haematological cancer; ii) Class I HDAC inhibitor domatinostat in combination with checkpoint blockade – translation of preclinical findings into the clinic\n\n\n\n\n9:45 am Modulation of the Lysine Specific Demethylase 1 with iadademstat and vafidemstat: Cancer\, Cognition and Behavior\n\nRobert Soliva\, Drug Discovery Director\, Oryzon Genomics\n\n\n\nSynopsis\n\nInhibition of LSD1 by irreversible binding to the FAD cofactor\nIadademstat for treatment of AML and SCLC\nIncreased of neuronal plasticity and improvement of cognitive and behavioral functions by treatment with vafidemstat\nModulation of LSD1 activity as a personalized medicine strategy in CNS disease.\n\n\n\n\n10:15 am Online speed networking\n\n\nSynopsis\nGrab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking! \n\n\n\n10:45 am Epigenetic Dual Targeting Compounds: Together is Better\n\nAntonello Mai\, Professor\, Spienza University of Rome\n\n\n\nSynopsis\n\nThe design and biological validation of compounds able to simultaneously hit two epigenetic targets will be discussed with their effects in cancer diseases\, in comparison with the single-target inhibitors.\n\n\n\n\n11:15 am Automated High-throughput ChIP-seq Workflow using Covaris Adaptive Focused Acoustics® System for Accelerated Epigenetic Drug Screening\n\nAlon Goren\, Assistant Professor\, Department of Medicine\, University of California San Diego\n\n\n\nSynopsis\n\nStreamlining and reduce workflow time using automated ChIP-seq with the Covaris Adaptive Focused Acoustics (AFA)\nEvaluation of the AFA technology in a range of epitopes\, including H3K4me3\, H3K27me3\, H3K27ac\, RNA Pol-II\, CTCF\, and HNF4A in different cell lines.\nHow to utilize AFA-based ChIP-seq processes for rapid epigenetic drug screening and clinical diagnostics\n\n\n\n\n11:30 am Targeting epigenetic adaptation in ovarian cancer\n\nRobert Brown\, Professor\, Imperial College London\n\n\n\nSynopsis\n\nImproving treatment of ovarian cancer is a major clinical unmet need.\nEpigenetic adaptation is a driver of drug resistance in ovarian cancer.\nPotential of histone methyltransferases to overcome drug resistance.\nModulation of the immune microenvironment by histone methyltransferases.\n\n\n\n\n11:50 am The use of epigenetic therapy to improve the efficacy of immune checkpoint therapy for multiple common cancer types\n\nStephen Baylin\, Professor of Oncology\, John Hopkins University\n\n\n\n\n\n12:10 pm Panel: Combination Therapies vs Monotherapies – Approaches with epigenetic therapies\n\nRobert Brown\, Professor\, Imperial College London\nStephen Baylin\, Professor of Oncology\, John Hopkins University\nIM Bennani-Baiti\, President & CEO\, Cancer Epigenetics Society\n\n\n\nSynopsis\n\nCan HDAC inhibitors really work as a monotherapy?\nClinical trial implications of combination therapies\n\n\n\n\n12:40 pm Panel: Our Social Media Feeds Are Personalized – Why Isn’t Our Medical Treatment?\n\nElisabetta Chiarparin\, Director of Oncology Chemistry and Programme Leader\, AstraZeneca\nPeter Atadja\, Director & Head\, Drug Discovery \, Novartis\nRobert Copeland\, President\, Chief Scientific Officer and Co-Founder \, Accent Therapeutics\nRajarshi Choudhury\, Genome Editing Investigator\, GSK\n\n\n\nSynopsis\n\nThe journey to personalized medicine and the role epigenetics will play \nHow to design a drug development pipeline for precision medicine \nThe future of personalised medicine – a pipe dream or legitimate goal? \n\n\n\n\n1:20 pm Online speed networking\n\n\nSynopsis\nAutomated online speed networking – randomized matches made automatically based on profile – 5 rounds of 3 mins – to help people “accidentally meet”. \n\n\n\n1:50 pm Panel: Toxicity and Off-Target Effects\n\nNeil Michaud\, Senior Director\, Translational Medicine\, Epizyme\nPaul Kayne\, Head\, Discovery Genomics & Proteomics\, Bristol-Myers Squibb\nKai He\, Assistant Professor of Medicine The Ohio State\, University College of Medicine\nTamara Maes\, CSO\, VP and founder\, Oryzon Genomics\n\n\n\nSynopsis\n\nOvercoming the obstacles of toxicity regardless of target \nTechniques for monitoring toxicity and balancing this with efficacy \nDebating the dangers of off-target effects versus on-target effects \n\n\n\n\n2:30 pm Case Study: The Tazemetostat Story\n\nNeil Michaud\, Senior Director\, Translational Medicine\, Epizyme\n\n\n\nSynopsis\n\nDesigning a successful clinical trial – balancing efficacy and safety\nPatient cohorts based on a diagnostic tool that identifies patients with specific EZH2 mutations\nFuture implications\, plans and the move towards precision medicine in oncology\n\n\n\n\n3:00 pm Selective Bromodomain Inhibition with the Bromodomain and Extraterminal Domain Inhibitor Apabetalone: Discovery to Phase 3 Cardiovascular Outcomes Study\n\nNorman Wong\, Co-Founder and CSO\, Resverlogix Corp\n\n\n\nSynopsis\n\nEpigenetic regulation and BET system in CVD/T2DM\nMechanism of Apabetalone\nHighlights of Pre-clinical and Clinical Data\n\n\n\n\n3:30 pm Targeting SMARCA4-mutant lung cancers through selective\, chemically-induced degradation of SMARCA2\n\nRobert Yauch\, Director & Principal Scientist\, Discovery Oncology\, Genentech\n\n\n\nSynopsis\n\nSMARCA4 is mutationally-inactivated in subsets of lung cancer leading to a dependency on the paralog helicase\, SMARCA2\nThe discovery and development of selective SMARCA2 inhibitors would be essential for therapeutically targeting SMARCA4-mutant lung cancers\nIn vitro characterization and demonstration of in vivo activity of potent and selective degraders of SMARCA2\n\n\n\n\n4:00 pm Targeting cancer therapy with an epigenetic drug: Pre-clinical and clinical experience\n\nRichard Trauger\, Senior Director Translational Medicine\, Viracta Therapeutics\n\n\n\nSynopsis\n\nSpecificity and properties of a compound in relation to clinical application\nCreating an oral drug and a dosing schedule that works\nVirus activation vs HDAC inhibitors\n\n\n\n\n4:30 pm Online Networking break\n\n\nSynopsis\nGrab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking! \n\n\n\n5:00 pm Design of combination strategies and identification of biomarkers associated with clinical response to the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients\n\nEric Campeau\, Senior Director\, Translational Medicine\, Zenith Epigenetics\n\n\n\nSynopsis\n\nOptimal combination agents to use with BET bromodomain inhibitors in the clinic\nPatient populations that can benefit from combinatorial therapies with ZEN-3694\nBiomarkers of response of ZEN-3694 + enzalutamide in mCRPC patients\n\n\n\n\n5:20 pm The antileukemic effect exerted by LSD1 inhibition\n\nHugh Young\, Reinhoff\, CEO\, Imago BioSciences\n\n\n\n\n\n5:40 pm Panel: The Role of Epigenetics in an Oncology Portfolio\n\nMahesh Karande\, President and CEO\, Omega Therapeutics\nSusan Wee\, Senior Director\, Oncology Drug Discovery\, Incyte\nEric Campeau\, Senior Director\, Translational Medicine\, Zenith Epigenetics\nHugh Young\, Reinhoff\, CEO\, Imago BioSciences\n\n\n\nSynopsis\n\nUtilizing epigenetics in combination with immunotherapies to further bolster the immune response\nBuilding a differentiated oncology portfolio based on standalone epigenetic (mono)therapies\nImagining the future of epigenetic therapies in oncology and beyond\n\n\n\n\n6:30 pm Close of virtual conference
URL:https://ces.b2sg.org/event/epigenetic-therapeutic-targets/
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2020/07/Epigenetics-Meeting-July-28_2020.jpg
ORGANIZER;CN="Hanson%20Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR